Calcitonin gene-related peptide (CGRP) inhibitors transformed migraine treatment after the first agent, Aimovig, received FDA approval in 2018. Eight CGRP-targeting drugs now hold FDA approvals spanning prevention and acute treatment, and the class generates billions in annual US revenue. But access remains heavily managed: prior authorization is required across most commercial and Medicaid plans, step therapy through older preventives is common, and payers generally will not cover concurrent use of multiple CGRP agents.
This landscape guide is for prescribers, access teams, pharmacists, and payer professionals who need a cross-CGRP view of coverage, prior authorization, step therapy, and cost trends.
FDA-approved CGRP inhibitors at a glance
| Parameter | Aimovig | Emgality | Ajovy | Vyepti | Nurtec ODT | Qulipta | Ubrelvy | Zavzpret |
|---|---|---|---|---|---|---|---|---|
| Generic name | Erenumab-aooe | Galcanezumab-gnlm | Fremanezumab-vfrm | Eptinezumab-jjmr | Rimegepant | Atogepant | Ubrogepant | Zavegepant |
| Manufacturer | Amgen | Eli Lilly | Teva | Lundbeck | Pfizer | AbbVie | AbbVie | Pfizer |
| Mechanism | mAb (CGRP receptor) | mAb (CGRP ligand) | mAb (CGRP ligand) | mAb (CGRP ligand) | Gepant (oral) | Gepant (oral) | Gepant (oral) | Gepant (nasal) |
| FDA approval | May 2018 | Sep 2018 | Sep 2018 | Feb 2020 | Feb 2020 (acute), May 2021 (prev) | Sep 2021 | Dec 2019 | Mar 2023 |
| Route | SC injection | SC injection | SC injection | IV infusion | Oral | Oral | Oral | Nasal spray |
| Dosing frequency | Monthly | Monthly | Monthly or quarterly | Quarterly | QOD (prev) or PRN (acute) | Daily | PRN (acute) | PRN (acute) |
| Use | Prevention | Prevention, cluster HA | Prevention, pediatric episodic migraine | Prevention | Prevention and acute | Prevention | Acute | Acute |
FDA-approved indications
| Indication | Aimovig | Emgality | Ajovy | Vyepti | Nurtec ODT | Qulipta | Ubrelvy | Zavzpret |
|---|---|---|---|---|---|---|---|---|
| Migraine prevention (adults) | Yes | Yes | Yes | Yes | Yes | Yes | No | No |
| Episodic cluster headache | No | Yes | No | No | No | No | No | No |
| Acute migraine | No | No | No | No | Yes | No | Yes | Yes |
| Pediatric (age 6-17) | No | No | Yes (episodic migraine, ≥45 kg) | No | No | No | No | No |
Teva's Ajovy became the first CGRP inhibitor to receive a pediatric indication in August 2025, approved for preventive treatment of episodic migraine in patients aged 6 to 17 years weighing 45 kg or more.
Pricing and cost
CGRP inhibitors are expensive branded specialty drugs. Wholesale acquisition cost (WAC) pricing for 30-day supplies as of early 2026:
| Drug | Approximate monthly WAC | Approximate annual WAC | Notes |
|---|---|---|---|
| Aimovig | $753 | $9,036 | 70 mg or 140 mg autoinjector |
| Emgality | $677 | $8,124 | 120 mg pen |
| Ajovy | $733 | $8,796 | 225 mg monthly or 675 mg quarterly |
| Vyepti | $603 | $7,236 | 100 mg or 300 mg IV quarterly |
| Nurtec ODT | $1,873 (prevention) | ~$11,238 | 48 tablets per 90 days (prevention) |
| Qulipta | $1,093 | $13,116 | 30 tablets (daily dosing) |
| Ubrelvy | ~$1,139 (10 tabs) | Varies by use | PRN acute use; max 16 tabs/30 days |
| Zavzpret | Pricing comparable to Ubrelvy | Varies by use | PRN acute; max 6 units/30 days |
Despite high list prices, net costs after rebates and discounts are substantially lower. The American Headache Society notes that copays for CGRP inhibitors on commercial plans can reach $300 to $600 per month when placed on specialty tiers.
In March 2025, the FDA updated safety labeling for all CGRP monoclonal antibodies and gepants to include warnings about the potential for developing or worsening hypertension and Raynaud's phenomenon.
Formulary placement and prior authorization
Commercial insurance
CGRP inhibitors are uniformly placed on specialty tiers and require prior authorization. Payer policies share common structural elements but differ in preferred-agent designations and step therapy requirements.
| Payer | Preferred preventive agents | Step therapy requirement | Notes |
|---|---|---|---|
| UnitedHealthcare | Emgality (migraine), Ajovy (pediatric) | 2+ prior preventive failures | No concurrent CGRP use; 12-month auth |
| Aetna (Medicaid) | Emgality 120 mg | Failure of 1 preferred injectable | Non-preferred: Aimovig, Ajovy, Vyepti |
| Prime Therapeutics | Varies by plan | Episodic: Aimovig, Ajovy, Emgality, Qulipta preferred | Acute: Nurtec ODT, Ubrelvy, Zavzpret preferred |
| Highmark | Varies | 2+ distinct preventive classes failed | Qulipta and Aimovig carry specific criteria |
| BCBS Michigan | Emgality preferred | Step therapy through preferred agent | Reauthorization requires 50% reduction or 4-5 fewer migraine days |
| Cigna | No step therapy for preventives | PA required but no prior preventive failures needed | Covers Aimovig, Emgality, Vyepti, Nurtec, Qulipta, Ajovy without step edits |
| CVS Caremark | Plan-dependent | PA required for all CGRP agents | Specialty pharmacy routing common |
Typical prior authorization criteria for migraine prevention
Across commercial payers, PA criteria for injectable CGRP preventives share these common elements:
- Patient is 18 years or older (or within FDA-label age range)
- Documented diagnosis of episodic (4-14 headache days/month) or chronic migraine (15+ days/month)
- Prescribed by or in consultation with a neurologist or headache specialist
- Documented trial and failure, intolerance, or contraindication to at least two prior preventive medication classes (e.g., beta-blockers, anticonvulsants, tricyclic antidepressants)
- Not used in combination with another CGRP inhibitor or antagonist
- Authorization typically granted for 6-12 months; reauthorization requires demonstrated clinical response (reduction in headache frequency and/or intensity)
Typical PA criteria for acute CGRP treatments (Nurtec ODT, Ubrelvy, Zavzpret)
- Patient is 18 years or older
- Documented diagnosis of migraine
- Trial and failure of at least two chemically distinct triptans
- Not used concurrently with another CGRP antagonist for acute treatment
- Quantity limits apply: Nurtec ODT max 8 tablets/30 days (acute) or 16/30 days (prevention), Ubrelvy max 16 tablets/30 days, Zavzpret max 6 units/30 days
Medicaid
State Medicaid programs actively manage CGRP access. Mississippi Medicaid (effective February 2026) provides a representative example of typical criteria:
- Preferred preventive agents: Aimovig, Ajovy, Emgality
- Acute treatment requires trial and failure of two chemically distinct triptans
- Initial authorization period of 6 months; reauthorization requires documented positive response
- Utah Medicaid requires trial and failure of two preventive classes (beta-blocker, anticonvulsant, tricyclic antidepressant, or venlafaxine) and failure of at least two triptans before acute CGRP approval
Dual-therapy restrictions
Payers uniformly prohibit concurrent use of multiple CGRP inhibitors. For example, a 2026 Michigan DIFS review upheld HAP's denial of Nurtec ODT for a patient already receiving Aimovig, citing the plan's one-CGRP-at-a-time policy.
Some plans do allow dual therapy in limited circumstances:
- A preventive injectable CGRP (e.g., Aimovig) combined with an acute oral triptan
- A preventive CGRP combined with an acute CGRP only after documented failure of at least two preventive CGRP agents, per Federal Employee Program (FEP Blue) policy effective July 2025
Patient assistance and copay support
All CGRP manufacturers offer copay assistance and patient support programs:
| Drug | Copay card program | Eligibility notes |
|---|---|---|
| Aimovig | Aimovig Ally | Commercially insured patients; income limits apply |
| Emgality | Lilly Answers | Commercial patients; $0 copay eligible for some |
| Ajovy | Teva Shared Solutions | Commercial patients; support for both SC formulations |
| Vyepti | Lundbeck patient support | Commercially insured; assistance with benefit investigation |
| Nurtec ODT | Pfizer copay savings | Commercial patients; not valid for government-funded plans |
| Qulipta | AbbVie copay assistance | Commercially insured patients |
| Ubrelvy | AbbVie copay assistance | Commercial patients; maximum benefit limits apply |
| Zavzpret | Pfizer copay savings | Commercially insured patients |
For uninsured or underinsured patients, manufacturer patient assistance programs (PAPs) may provide free medication based on income eligibility. Patients and providers should verify current program terms directly, as eligibility criteria and benefit caps change periodically.
What to monitor
Ajovy pediatric label expansion. The August 2025 pediatric approval for episodic migraine (ages 6-17, ≥45 kg) could shift payer policies for pediatric populations and potentially expand Ajovy's formulary preference.
Biosimilar and generic timeline. CGRP monoclonal antibodies are not expected to face biosimilar competition until the early-to-mid 2030s (Ajovy biosimilar entry estimated 2033-2036). However, gepant small molecules may face generic entry sooner depending on patent outcomes.
Safety labeling updates. The March 2025 FDA safety update adding hypertension and Raynaud's phenomenon warnings to all CGRP agents may influence payer coverage criteria and prescriber behavior.
IRA and Medicare negotiation. No CGRP inhibitor is currently on the IRA negotiated-price list, but the class's high Part D spend makes future selection plausible as the program expands.
New oral CGRP agents. Pipeline oral CGRP receptor antagonists could further segment the market and potentially drive price competition within the gepant sub-class.
Sources
- FDA. "Aimovig (erenumab-aooe) prescribing information." March 2025. https://www.aimovig.com
- FDA. "Emgality (galcanezumab-gnlm) prescribing information." May 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761113s016lbl.pdf
- Teva Pharmaceuticals. "FDA Approves Expanded Indication for AJOVY." August 6, 2025. https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2025/FDA-Approves-Expanded-Indication-for-AJOVY-fremanezumab-vfrm-The-First-Anti-CGRP-Preventive-Treatment-for-Pediatric-Episodic-Migraine/default.aspx
- UnitedHealthcare. "CGRP Receptor Antagonists Prior Authorization." Program 2026 P 2146-15, effective April 1, 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/a-g/PA-Med-Nec-CGRP-Receptor-Antagonists.pdf
- Aetna Better Health. "CGRP Antagonists Injectable IV Infusion Coverage Policy." Effective February 2, 2026. https://www.aetnabetterhealth.com/content/dam/aetna/medicaid/pdfs/formulary/guidelines/CGRP-Antagonist-Injectable-IV-Infusion-Aetna-Medicaid-Policy-ua.pdf
- Prime Therapeutics. "CGRP Prior Authorization with Quantity Limit Program Summary." Boeing Commercial, effective January 1, 2026. https://www.myprime.com/content/dam/prime/memberportal/forms/AuthorForms/Boeing/Program_Summaries/Boeing_CGRP_PAQL_ProgSum.pdf
- Mississippi Division of Medicaid. "Calcitonin Gene-Related Peptides (CGRP) Inhibitors PA Criteria." Version 15, effective February 1, 2026. https://medicaid.ms.gov/wp-content/uploads/2026/01/CGRP-02_01_2026-to-Current.V15.pdf
- State of Michigan DIFS. "PRIRA Review, HAP 243688." February 2026. https://www.michigan.gov/difs/-/media/Project/Websites/difs/PRIRA/2026/February/HAP_243688.pdf
- PMC. "CGRP and Migraine: Real World Insights and Future Therapeutic Directions." 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12818195
- Oregon PDAB. "Ajovy (fremanezumab-vfrm) Drug Price Review." 2025. https://dfr.oregon.gov/pdab/Documents/Ajovy.pdf
